Division of Sanofi
Latest From Genzyme BV
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for EU marketing authorizations.
Novartis’s Cosentyx and Celgene’s Otezla are expected to be approved and launched in Europe in early 2015 for the dermatological indication.
CHMP has released for the first time the minutes of its meeting, and EMA has set up a new pharmacovigilance cluster with the FDA. A biosimilar infliximab product from Hospira and Alvogen has become the first biosimilar monoclonal antibody launched in Europe.
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Senior Management
Jan van Heek, VP & General Manager
Erik Tambuyzer, PhD, VP, Diagnostics Business Dev., Europe
- Contact Info
Phone: (31) 2159 50102
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.